See more : Muro Corporation (7264.T) Income Statement Analysis – Financial Results
Complete financial analysis of Nanobiotix S.A. (NBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Nanobiotix S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PT Perusahaan Gas Negara Tbk (PPAAF) Income Statement Analysis – Financial Results
- Entergy Texas, Inc. (ETI-P) Income Statement Analysis – Financial Results
- Al Khaleej Training and Education Company (4290.SR) Income Statement Analysis – Financial Results
- GCS Holdings, Inc. (4991.TWO) Income Statement Analysis – Financial Results
- Ball Corporation (BLL) Income Statement Analysis – Financial Results
Nanobiotix S.A. (NBTX)
About Nanobiotix S.A.
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 30.06M | 4.78M | 10.00K | 50.00K | 68.00K | 116.00K | 251.97K | 1.56M | 265.54K | 967.50K | 184.94K | 74.15K | 1.36M |
| Cost of Revenue | 0.00 | 985.00K | 0.00 | 0.00 | 0.00 | 0.00 | 345.59K | 436.31K | 359.61K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 30.06M | 3.79M | 10.00K | 50.00K | 68.00K | 116.00K | -93.62K | 1.12M | -94.07K | 967.50K | 184.94K | 74.15K | 1.36M |
| Gross Profit Ratio | 100.00% | 79.38% | 100.00% | 100.00% | 100.00% | 100.00% | -37.16% | 72.00% | -35.42% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 38.40M | 32.64M | 30.38M | 24.33M | 30.41M | 20.89M | 16.34M | 16.92M | 13.90M | 8.08M | 6.03M | 4.31M | 5.21M |
| General & Administrative | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 21.66M | 17.48M | 19.43M | 14.27M | 18.64M | 12.62M | 12.34M | 10.26M | 7.19M | 4.30M | 3.61M | 1.81M | 1.30M |
| Other Expenses | -3.22M | -3.41M | -2.64M | -2.07M | -2.20M | -3.33M | -337.89K | 160.23K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Cost & Expenses | 56.84M | 46.70M | 47.18M | 36.53M | 46.85M | 30.18M | 25.52M | 23.41M | 17.41M | 10.59M | 8.36M | 5.23M | 5.23M |
| Interest Income | 1.22M | 256.00K | 6.17M | 4.68M | 105.00K | 34.00K | 33.03K | 59.49K | 183.22K | 196.65K | 59.06K | 46.00 | 11.53K |
| Interest Expense | 7.98M | 5.84M | 590.00K | 333.00K | 4.79M | 847.00K | 108.37K | 102.20K | 59.52K | 55.73K | 24.57K | 77.01K | 30.77K |
| Depreciation & Amortization | 1.51M | 1.50M | 1.56M | 1.76M | 1.77M | 569.00K | 345.59K | 436.31K | 456.08K | 307.56K | 233.93K | 146.53K | 197.62K |
| EBITDA | -30.09M | -45.15M | -45.61M | -31.49M | -44.78M | -29.33M | -25.55M | -21.21M | -16.49M | -9.11M | -7.89M | -5.01M | -5.02M |
| EBITDA Ratio | -100.09% | -1,084.63% | -409,950.00% | -59,906.00% | -65,845.59% | -25,282.76% | -10,172.33% | -1,360.96% | -6,208.97% | -942.01% | -4,264.36% | -6,781.21% | -368.90% |
| Operating Income | -26.78M | -46.70M | -52.58M | -36.43M | -46.78M | -30.07M | -25.27M | -21.85M | -17.14M | -9.62M | -8.18M | -5.15M | -5.23M |
| Operating Income Ratio | -89.09% | -977.85% | -525,790.00% | -72,856.00% | -68,792.65% | -25,919.83% | -10,027.88% | -1,402.65% | -6,455.32% | -994.29% | -4,422.79% | -6,948.91% | -384.27% |
| Total Other Income/Expenses | -12.80M | -10.33M | 5.58M | 2.85M | -4.13M | -278.00K | -876.00K | 64.61K | 138.56K | 142.52K | 34.50K | -99.18K | -19.34K |
| Income Before Tax | -39.58M | -57.03M | -47.00M | -33.61M | -50.91M | -30.35M | -26.14M | -21.79M | -17.00M | -9.48M | -8.14M | -5.25M | -5.25M |
| Income Before Tax Ratio | -131.68% | -1,194.16% | -469,990.00% | -67,228.00% | -74,870.59% | -26,159.48% | -10,375.61% | -1,398.50% | -6,403.14% | -979.56% | -4,404.14% | -7,082.66% | -385.69% |
| Income Tax Expense | 120.00K | 10.00K | 5.00K | 9.00K | 3.00K | -449.00K | 20.00 | 90.43K | 37.58K | 79.27K | 22.91K | 78.89K | 30.67K |
| Net Income | -39.70M | -57.04M | -47.00M | -33.62M | -50.92M | -29.90M | -26.14M | -21.88M | -17.00M | -9.56M | -8.14M | -5.33M | -5.25M |
| Net Income Ratio | -132.08% | -1,194.37% | -470,040.00% | -67,246.00% | -74,875.00% | -25,772.41% | -10,375.62% | -1,404.31% | -6,403.14% | -987.75% | -4,404.14% | -7,189.05% | -385.69% |
| EPS | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| EPS Diluted | -1.08 | -1.64 | -1.35 | -1.38 | -2.35 | -1.52 | -1.50 | -1.43 | -1.20 | -0.74 | -0.76 | -0.65 | -3.42 |
| Weighted Avg Shares Out | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.62M | 17.43M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
| Weighted Avg Shares Out (Dil) | 36.93M | 34.85M | 34.73M | 24.39M | 21.63M | 19.63M | 17.48M | 15.28M | 14.14M | 12.87M | 10.75M | 8.22M | 1.54M |
NANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
PARIS and CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided...
NANOBIOTIX to Participate in Multiple Investor Conferences in November
~ Guggenheim's Inaugural Healthcare Innovation Conference, Nov 11-13 ~ ~ Stifel Healthcare Conference, Nov 18-19 ~ ~ Jefferies London Healthcare Conference, Nov 19-21 ~ PARIS and CAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX –...
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
PARIS and CAMBRIDGE, Mass., Sept. 18, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, provided...
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
PARIS and CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases,...
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management...
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
PARIS and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases,...
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
PARIS and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases,...
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
PARIS and CAMBRIDGE, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management...
Nanobiotix S.A. (NBTX) Q1 2024 Earnings Call Transcript
Nanobiotix S.A. (NASDAQ:NBTX ) Q1 2024 Earnings Conference Call May 22, 2024 8:00 AM ET Company Participants Craig West - SVP, IR Laurent Levy - Co-Founder and CEO Bart Van Rhijn - CFO Conference Call Participants Jonathan Chang - Leerink...
Source: https://incomestatements.info
Category: Stock Reports